# Premedication to Reduce Amivantamab Associated Infusion Related Reactions

> **NCT05663866** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 68 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Montelukast
- **DRUG:** Methotrexate
- **DRUG:** Amivantamab
- **DRUG:** Lazertinib

## Key facts

- **NCT ID:** NCT05663866
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-18
- **Primary completion:** 2024-03-29
- **Final completion:** 2026-07-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05663866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05663866, "Premedication to Reduce Amivantamab Associated Infusion Related Reactions". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05663866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*